dc.description.abstract |
One of the main challenges of therapeutic tools for the treatment of parasitic
diseases, including leishmaniasis, is the interwinned relationship between therapeutic
failure and drug resistance. In fact, some field parasites might be naturally
resistant to classical drugs and additionally, current therapies may induce drug
resistance. In fact, treatment failure in leishmaniasis has multiple causes. Some
are related to drugs, such as pharmacokinetic properties, toxicity, use of
sub-optimal doses, or high cost of treatment. Parasite-related grounds include
chemo-resistance and tolerance. Last but not least, the host plays a fundamental
role in this situation since the patient's immune status and the risk of re-infection
if living in an endemic region might also contribute to therapeutic failure. All
these features are at least partially responsible for the disappointing persistence
and re-emergence of leishmaniasis, as well as its death and disability-adjusted life
year toll worldwide. A better understanding of the disease itself and of drug
resistance, its molecular basis, its consequences, and the definition of possible
paths for better treatments may help improve this depressing picture. In the
present volume experts in the field cover current knowledge and future trends
of these and many other aspects of drug resistance in Leishmania. This initial
chapter offers a general introduction to the biology of the parasite, a piece of
information fundamental for the topics included in the book and the comprehension
of challenges we currently face for this disease |
es_ES |